- News article -

Customer success-story: Optomed secured 1,97 M€ EU funding for Smartscope-X – affordable, accessible and automatic screening for diabetic retinopathy

12 Oct 2017

In May, the Finnish medical technology company Optomed was granted 1,97 M€ from Horizon 2020 SME Phase 2 instrument under the topic Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well. The funding will help Optomed make their product Smartscope-X the leading solution for diabetic retinopathy screening, supporting the company’s vision to provide affordable eye screenings to everyone.

Diabetic retinopathy is the most frequent cause of preventable blindness in working-aged adults, affecting people with all types of diabetes. Visual impairment and blindness caused by diabetic retinopathy can be prevented through early and effective screening. Currently, screening is costly, time-consuming and needs to be done by an ophthalmologist. Optomed’s solution will allow patients to do the screenings automatically and get the diagnosis in real-time.

Optomed’s fully automated diabetic retinopathy screening solution consists of three main components: a low-cost handheld camera, an automated screening algorithm and a cloud service for eyeground images. As a low-cost and portable solution, Smartscope-X can also provide access to screening for example in developing countries.

Spinverse supported Optomed in project preparation, including help in defining the scope, matching the call and assisting in writing the proposal. After a positive decision from the EU Commission in May 2017, Spinverse supported Optomed in the project negotiation phase.

“The cooperation with Spinverse worked well. The applicant always has the main responsibility during the application process, but the support from Spinverse and their expertise on the application process helped us achieve the desired outcome,” says Seppo Kopsala, CEO of Optomed.

The project officially began in August. Currently, Optomed is working on product development related to the integration between the camera and the software as well as choosing subcontractors for the server solution. Next steps towards the commercialization of Smartscope-X include several clinical tests and commercial pilots in target countries during 2018–2019.

What can you achieve with EU funding? See how we have helped companies create success stories and  contact us to discuss your options.

Photo credit: Optomed

- News -

Relevant posts

Client News digital healthcare health technology

Healthcare projects within CleverHealth Network are moving forward

29 Jun 2020

The CleverHealth Network ecosystem is buzzing with activity as the ongoing six co-development projects aim t...

Client News ECSEL open innovation ecosystem

CHARM project develops IoT solutions for harsh industrial environments

22 Jun 2020

The CHARM ECSEL JU project coordinated by Valmet aims to develop industrial IoT solutions with an improved t...

Client News Public Funding innovation ecosystem

Spinverse supports Nokia in building their winning ecosystem project for unlocking Industrial 5G

18 Jun 2020

Business Finland launched a competition in early 2020 for leading companies (so called Veturi companies) wit...

circular economy Client News innovation ecosystem

Spinverse supports Fortum and Metsä Group in the launch of a joint EUR 50 million circular bioeconomy programme

18 Jun 2020

Spinverse customers Fortum and Metsä Group join forces with Business Finland to create a world-class R&...

Our People Spinverse News

New colleagues that we have not yet met face to face

11 Jun 2020

In the midst of the pandemic, Spinverse welcomed several new colleagues onboard. Some of them started as per...

EU funding Public Funding innovation fund

Innovation Fund supports emission reductions in Europe

5 Jun 2020

The European Commission has announced a remarkable investment programme worth 10 B€ or more, focusing on h...